Medical Design Technology
03/03/2015
Megan Crouse, Real Time Digital Reporter, @abmdigi
Cyfuse Biomedical K.K., makers of a 3D printer for living cells, have reported 1.4 billion yen ($12 million) in Series B funding for its overseas operations.
Cyfuse’s Regenova printer uses an array of needles to skewer cellular aggregates. Once the cellular aggregates are fused together, the needles are removed, resulting in elastic, organic material made from the original cells and the connective protein collagen. Then, the cell structure matures for several days or weeks in a customized bioreactor, until it has reached its target structure and function.
The 3D-printed cells are designed for use in drug discovery research and regenerative medicine. Printed in this way, they produce thicker and more elastic tissue than has been conventionally available for testing. The technology can be used with various cell types.
Cyfuse’s products include both the Regenova bio 3D printer and 3D tissue products, which are sold primarily to Japanese universities. The company also researches and develops 3D tissue products. With the new round of funding, Cyfuse plans to establish a cell processing facility for clinical use, where its 3D printer technology can be used to subcontract manufacturing of tissue for university and hospital use. It will also help with the Japanese company’s plan to sell the Regenova 3D printer overseas.
The total investment in Cyfuse since the startup founded in 2010 has been 1.98 billion yen ($16 million), including capital reserve.
The company was founded based on the research of Professor Koichi Nakayama of Saga University. Cyfuse has been supported in the past by the Japan Science and Technology Agency and the New Energy and Industrial Technology Development Organization.
03/03/2015
Megan Crouse, Real Time Digital Reporter, @abmdigi
Cyfuse Biomedical K.K., makers of a 3D printer for living cells, have reported 1.4 billion yen ($12 million) in Series B funding for its overseas operations.
Cyfuse’s Regenova printer uses an array of needles to skewer cellular aggregates. Once the cellular aggregates are fused together, the needles are removed, resulting in elastic, organic material made from the original cells and the connective protein collagen. Then, the cell structure matures for several days or weeks in a customized bioreactor, until it has reached its target structure and function.
The 3D-printed cells are designed for use in drug discovery research and regenerative medicine. Printed in this way, they produce thicker and more elastic tissue than has been conventionally available for testing. The technology can be used with various cell types.
Cyfuse’s products include both the Regenova bio 3D printer and 3D tissue products, which are sold primarily to Japanese universities. The company also researches and develops 3D tissue products. With the new round of funding, Cyfuse plans to establish a cell processing facility for clinical use, where its 3D printer technology can be used to subcontract manufacturing of tissue for university and hospital use. It will also help with the Japanese company’s plan to sell the Regenova 3D printer overseas.
The total investment in Cyfuse since the startup founded in 2010 has been 1.98 billion yen ($16 million), including capital reserve.
The company was founded based on the research of Professor Koichi Nakayama of Saga University. Cyfuse has been supported in the past by the Japan Science and Technology Agency and the New Energy and Industrial Technology Development Organization.